Accepted for Publication: June 6, 2022.
Published: July 21, 2022. doi:10.1001/jamanetworkopen.2022.23401
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Zhang XS et al. JAMA Network Open.
Corresponding Author: Quoc Dinh Nguyen, MD, MPH, PhD, Division of Geriatrics, Department of Medicine, Centre hospitalier de l’Université de Montréal, 1000 rue Saint-Denis, Montreal, QC H2X 0C1, Canada (quoc.dinh.nguyen@umontreal.ca).
Author Contributions: Dr Nguyen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Zhang, Moreau, Nguyen.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Nguyen.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Nguyen.
Administrative, technical, or material support: Zhang, Moreau, Cruz-Santiago, Nguyen.
Supervision: Zhang, Moreau, Nguyen.
Conflict of Interest Disclosures: None reported.
2.Hause
AM , Baggs
J , Marquez
P ,
et al. Safety monitoring of COVID-19 vaccine booster doses among adults — United States, September 22, 2021–February 6, 2022.
MMWR Morb Mortal Wkly Rep. 2022;71(7):249-254. doi:
10.15585/mmwr.mm7107e1PubMedGoogle ScholarCrossref 4.Atmar
RL , Lyke
KE , Deming
ME ,
et al; DMID 21-0012 Study Group. Homologous and heterologous Covid-19 booster vaccinations.
N Engl J Med. 2022;386(11):1046-1057. Published online January 26, 2022. doi:
10.1056/NEJMoa2116414PubMedGoogle ScholarCrossref 6.Munro
APS , Janani
L , Cornelius
V ,
et al; COV-BOOST study group. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet. 2021;398(10318):2258-2276. doi:
10.1016/S0140-6736(21)02717-3PubMedGoogle ScholarCrossref